mortality/aging
|
• 6 months after tamoxifen treatment, mice develop intestinal disease and eventually die or are sacrificed
|
digestive/alimentary system
|
• tamoxifen-treated mice exhibit partial or complete fibrosis of the small intestine and cecum unlike in wild-type mice with increased submucosal connective tissue and proportional increase in fibroblast-like cells and collagenous matrix
|
|
• tamoxifen-treated mice exhibit partial or complete fibrosis of the small intestine and cecum unlike in wild-type mice with increased submucosal connective tissue and proportional increase in fibroblast-like cells and collagenous matrix
|
|
• tamoxifen-treated mice exhibit partial or complete fibrosis of the small intestine and cecum unlike in wild-type mice with increased submucosal connective tissue and proportional increase in fibroblast-like cells and collagenous matrix
|
|
• in tamoxifen-treated mice
|
cardiovascular system
|
• in tamoxifen-treated mice
|
renal/urinary system
|
• sclerotic glomeruli in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• enlarged glomeruli in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
neoplasm
|
• at between 44 and 76 weeks of age, 5 of 29 tamoxifen-treated mice develop sarcomas arising from dermis or muscle connective tissue
|
muscle
|
• in tamoxifen-treated mice
|
respiratory system
|
• around the bronchioles in tamoxifen-treated mice
|
integument
tight skin
(
J:146617
)
|
• in tamoxifen-treated mice
|


Analysis Tools